Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation.
Lab research · 2022
- What was studied
- Cultured-cell injury and receptor-blockade experiments
- Main finding
- AMPA and Trk receptor blockers prevented the reported CPG neuroprotective effect in cultured-cell experiments. Pharmacological blockade supports pathway involvement, not a fully resolved mechanism.
Study data at a glance
- Participants or experimental model
- Cultured-cell injury and receptor-blockade experiments
- Reported results
- AMPA and Trk receptor blockers prevented the reported CPG neuroprotective effect in cultured-cell experiments. Pharmacological blockade supports pathway involvement, not a fully resolved mechanism.
Study limitations and source details
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Source details
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Abstract reviewed
Sources checked
Citation
Gudasheva TA, Koliasnikova KN, Alyaeva AG, Nikolaev SV, Antipova TA, Seredenin SB. Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation. Doklady. Biochemistry and biophysics
Study source ↗ · DOI 10.1134/s1607672922060047 · Bibliography entry · Link to this summary